Episodios

  • Hemophilia B Gene Therapy: Can Beqvez (Fidanacogene) End the Infusion Cycle?
    Jun 21 2025

    What if the the cutting-edge science behind Beqvez, including its AAV vector and the high-activity FIX-Padua variant, relentless cycle of infusions for Hemophilia B could finally pause, allowing your own body to take the reins? 🩸➡️ what clinical trials revealed about its potential to reduce bleeding rates and reliance on prophylaxis ❤️, and the crucial patient eligibility criteria like💪

    In this episode of March Forward, we explore Fidanacogene Elaparvovec (brand name: Be neutralizing antibody screening. We’ll also delve into the often-unseen market challenges 🔬 that even clinically successful therapiesqvez), a gene therapy that offered significant promise for individuals with Hemophilia B. We delve into the innovative science designed can face, providing a balanced look at this important story.

    Join us as we discuss the impact of Fidanacogene Elaparvovec, its place in the evolving landscape of Hemophilia B treatments, and the lessons learned from its journey. If you're passionate about medical advancements for rare diseases or want to understand the intricate path new therapies take, this episode is for you! 💪

    Don't forget to subscribe to March Forward for more insights from our community run by patients, for patients. Like this episode, share your thoughts or questions in the comments below – we're all in this together.


    #HemophiliaB #Beqvez #FidanacogeneElaparvovec #GeneTherapy #FactorIX #RareDisease #ClinicalTrials #PatientCommunity #MedicalAdvancements #DrugDevelopment #HealthcareEconomics #MarchForward #FIXPadua #AAVGeneTherapy #RareDiseaseAwareness #MedicalPodcast

    Hosted on Acast. See acast.com/privacy for more information.

    Más Menos
    38 m
  • Tecelra (Afamitresgene Autoleucel): How Your Immune Cells Can Be Trained to Fight Synovial Sarcoma
    Jun 14 2025

    What happens when standard treatments for a rare cancer like synovial sarcoma fall short? Could the answer lie in empowering your own immune system? 🛡️

    In this episode of March Forward, we explore Afamitresgene Autoleucel (Tecelra), an innovative cell therapy offering a new avenue of hope ✨ for patients with advanced synovial sarcoma. This cutting-edge treatment takes a patient's own immune cells, 're-educates' them in a lab to specifically target cancer cells (targeting MAGE-A4, a protein often found in synovial sarcoma), and then reinfuses them as a personalized fighting force.

    Learn how this highly specialized approach works, its potential impact on managing this rare cancer ❤️, and what it could mean for the future of personalized medicine in oncology. We'll break down this complex science 🔬 in an understandable way, always focusing on the patient perspective, the journey involved, and the careful considerations of such advanced therapies.

    Join us as we discuss Tecelra's role in the fight against synovial sarcoma. If you or a loved one are navigating this rare cancer, or you’re interested in the latest breakthroughs in immunotherapy and cell therapies, this episode is for you! 💪

    Don't forget to subscribe to March Forward for more insights from our community run by patients, for patients. Like this episode, share your thoughts or questions in the comments below, and visit our website at march.ai.

    #SynovialSarcoma #Tecelra #AfamitresgeneAutoleucel #CellTherapy #CARTcell #Immunotherapy #RareCancer #CancerTreatment #PatientSupport #MarchForward #PersonalizedMedicine #Hope #MAGEA4 #Sarcoma



    Hosted on Acast. See acast.com/privacy for more information.

    Más Menos
    26 m
  • Can In-Body Gene Editing Help Cure Rare Genetic Diseases?
    Jun 10 2025

    What if we could gently fix the tiny genetic 'typos' that cause devastating rare diseases, right where they are in the body? 🧬

    In this episode of March Forward, we dive into In Vivo CRISPR Base Editing, a cutting-edge science offering a new horizon of hope ✨ for patients and families navigating rare genetic conditions. We explore how this groundbreaking technology aims to make ultra-precise changes to DNA inside the body, potentially correcting the root cause of certain diseases.

    Learn how this innovative approach differs from other gene editing techniques and what it could mean for the future of treating inherited disorders ❤️. We'll break down this complex science 🔬 in an understandable way, focusing on its potential, the journey of discovery, and the careful steps involved in bringing such advancements to those who need them most.

    Join us as we discuss the impact of In Vivo CRISPR Base Editing, the ongoing research, and the careful considerations for the rare disease community. If you're passionate about medical advancements or looking for information on emerging therapies that could one day change lives, this episode is a must-listen! 💪

    Don't forget to subscribe to March Forward for more insights from our community run by patients, for patients. Like this episode, and share your thoughts or questions in the comments below – we're all in this together.

    #CRISPR #BaseEditing #InVivoGeneEditing #GeneEditing #RareDisease #GeneticDisorders #PatientCommunity #MedicalAdvancements #FutureOfMedicine #Biotechnology #ScienceExplained #Hope #MarchForward #MarchCommunity #RareDiseaseAwareness #MedicalPodcast #HealthPodcast #PatientEmpowerment #GeneticResearch

    Hosted on Acast. See acast.com/privacy for more information.

    Más Menos
    33 m
adbl_web_global_use_to_activate_webcro805_stickypopup